Determinants of Compliance With Glaucoma Therapy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2011 by Legacy Health System.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by (Responsible Party):
Steven L. Mansberger, Legacy Health System
ClinicalTrials.gov Identifier:
NCT01484392
First received: November 30, 2011
Last updated: December 1, 2011
Last verified: November 2011

November 30, 2011
December 1, 2011
August 2006
December 2013   (final data collection date for primary outcome measure)
  • Compliance with glaucoma medication at 1 month [ Time Frame: 1 month after enrollment ] [ Designated as safety issue: No ]
    Compliance is measured using the Travatan Dosing Aid, a device that records when patients administer their topical glaucoma medication.
  • Compliance with glaucoma medication at 3 months [ Time Frame: 3 months after enrollment ] [ Designated as safety issue: No ]
    Compliance is measured using the Travatan Dosing Aid, a device that records when patients administer their topical glaucoma medication.
Same as current
Complete list of historical versions of study NCT01484392 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Determinants of Compliance With Glaucoma Therapy
Determinants of Compliance With Glaucoma Therapy

The purpose of this study is to determine which medical, demographic, and health belief factors are associated with glaucoma therapy compliance.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Patients diagnosed with open angle glaucoma.

Open Angle Glaucoma
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
60
December 2013
December 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • open angle glaucoma
  • be well controlled on current medical therapy
  • be using a prostaglandin analogue
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01484392
FWA00001280
No
Steven L. Mansberger, Legacy Health System
Legacy Health System
Not Provided
Principal Investigator: Steven L Mansberger, MD, MPH Legacy Health
Legacy Health System
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP